Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Sarcoma

1626MO - Treatment expectations and preferences for quality versus quantity of life in patients with advanced soft tissue sarcomas starting palliative 1st line chemotherapy

Date

18 Sep 2020

Session

Mini Oral - Sarcoma

Topics

Tumour Site

Soft Tissue Sarcomas

Presenters

Eugenie Younger

Citation

Annals of Oncology (2020) 31 (suppl_4): S914-S933. 10.1016/annonc/annonc288

Authors

E. Younger1, R.L. Jones2, D. Den Hollander3, V. Soomers4, I.M.E. Desar5, R. Young6, A. Oosten7, H. Gelderblom8, J.J. De Haan9, N. Steeghs10, O. Husson11, W.T.A. Van Der Graaf12

Author affiliations

  • 1 Sarcoma Unit, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 3 Medical Oncology, Radboud University Medical Centre Nijmegen, 6525 EX - Nijmegen/NL
  • 4 Medical Oncology, Radboud University Medical Center, 6525 GA - Nijmegen/NL
  • 5 Medical Oncology Dept., Radboud University Medical Centre Nijmegen Undo, 6500 HB - Nijmegen/NL
  • 6 Medical Oncology, Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, S10 2SJ - Sheffield/GB
  • 7 Medical Oncology Department, Erasmus MC Daniel den Hoed Cancer Center, 3000 CA - Rotterdam/NL
  • 8 Medical Oncology Dept, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL
  • 9 Medical Oncology Dept, University Hospital Groningen (UMCG), 9700 RB - Groningen/NL
  • 10 Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 11 Psychosocial Research And Epidemiology Department, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 12 Medical Oncology Department, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066 CX - Amsterdam/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1626MO

Background

Palliative chemotherapy is the mainstay of treatment for patients with advanced soft tissue sarcomas (STS), however prognosis is limited (median overall survival 12-19 months). In this setting, patient values and preferences -though understudied- are central to treatment decisions. Our objectives were to explore priorities for quality versus quantity (length) of life (QoL vs. LoL) and treatment expectations in patients starting chemotherapy (CTx).

Methods

The HOLISTIC study is an international prospective cohort study assessing health-related quality of life in advanced STS patients receiving palliative CTx. Participants completed a baseline questionnaire before starting 1st-line CTx, including treatment expectations and preferences for QoL vs. LoL. Chi-squared and Fisher’s exact tests were used to evaluate associations between patient characteristics, preferences and expectations.

Results

In total, 137 patients with advanced STS participated (U.K: n=72, Netherlands: n=65). Median age was 62 years (range 27-79). Preference for extended LoL (48%) was slightly more common than preference for QoL (41%); 9% valued LoL and QoL equally. Younger patients (aged<40 years; P=0.002) and those who were employed (P=0.019) prioritised LoL. U.K participants and those with dependent children tended to prioritise LoL, however, this trend was not statistically significant. Most patients thought that CTx would help them to live longer (88%), 27% believed CTx was potentially curative and 67% thought that it would improve cancer-related problems. Belief that treatment could be curative was more common among ‘non-Caucasian’ participants (n=22; P=0.016). Gender, marital status, education level, performance status, baseline health-related quality of life, disease extent and time period since advanced STS diagnosis were not associated with preferences or expectations.

Conclusions

These data show heterogenous preferences and expectations among advanced STS patients starting 1st line chemotherapy, supporting personalised decision making. Treatment regret will be a topic of further study.

Clinical trial identification

NCT03621332.

Editorial acknowledgement

Legal entity responsible for the study

Royal Marsden NHS Foundation Trust and Institute of Cancer Research.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.